The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a public listing that could see proceeds of around $210m. The cancer treatment-focused biotech ...

Initial public offerings are back in fashion, and the temptation is to treat every debut like a lottery ticket. In a market that rewards speed and narrative, the investors who actually keep their ...

Taking a technology company public is a milestone that brings both opportunity and complexity. While the spotlight often shines on the IPO day, it’s the careful orchestration behind the ...